ID   7G3
AC   CVCL_C3X5
DR   Wikidata; Q116048406
RX   PubMed=8547680;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized talacotuzumab (CSL362) therapeutic antibody which was used in clinical trials for the treatment of acute myeloid leukemia.
CC   Monoclonal antibody isotype: IgG2a.
CC   Monoclonal antibody target: UniProtKB; P26951; Human IL3RA/CD123.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2155 ! P3/NS1/1-Ag4.1
CA   Hybridoma
DT   Created: 15-12-22; Last updated: 21-03-23; Version: 2
//
RX   PubMed=8547680; DOI=10.1182/blood.V87.1.83.83;
RA   Sun Q.-Y., Woodcock J.M., Rapoport A.P., Stomski F.C., Korpelainen E.I.,
RA   Bagley C.J., Goodall G.J., Smith W.B., Gamble J.R., Vadas M.A.,
RA   Lopez A.F.;
RT   "Monoclonal antibody 7G3 recognizes the N-terminal domain of the human
RT   interleukin-3 (IL-3) receptor alpha-chain and functions as a specific
RT   IL-3 receptor antagonist.";
RL   Blood 87:83-92(1996).
//